Syncom Formulations (India) Ltd
SYNCOMFSyncom Formulations (India) Ltd's earnings have outrun its stock. EPS grew +52.8% in a year against a +8.5% price move.
The sharpest disagreement: profits are rising, but only 50% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (52 weeks in) while the P/E sits at the 52nd percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +56.3% year on year, and 50% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Syncom Formulations (India) Ltd trades at ₹19.5, in a downtrend and 52 weeks into that stage. That is +28.9% against its own 200-day average. It sits at 89% of a 52-week range of ₹11 to ₹21. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.
Today the stock is in a downtrend — week 52 of stage 4. At ₹19.5 it trades +28.9% versus its 200-day average and sits at 89% of its 52-week range (₹11–₹21).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +720% while the NIFTY 500 moved +273% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Syncom Formulations (India) Ltd trades at 21.4× P/E, mid-range by its own standards (52nd percentile). Its long-run median P/E is 20.0×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 21.4× is mid-range by its own standards (52nd percentile), against a long-run median of 20.0× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +52.8% against a +8.5% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +26.4%/yr price move, ~+45.4%/yr came from earnings growth and ~−19.0 pp from the multiple (compressing); over 10y, of the +22.4%/yr price move, ~+21.5%/yr came from earnings growth and ~+0.9 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Syncom Formulations (India) Ltd was paying for profit growth of about 8.3% a year. Profit itself has compounded 21.6% a year over the past 13 years. Today the market pays 21.4× P/E, the 52nd percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Syncom Formulations (India) Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +70.4% at its peak to +0.4% but is still expanding, ROCE lifting at 27.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.6% | +30.1% | — | +10.3% |
| Profit | +55.1% | +56.0% | — | +22.5% |
| EPS | +52.8% | +56.8% | — | +20.1% |
| Share price | +8.5% | +30.5% | +26.4% | +22.4% |
4-Factor Sector Score
64.2/100 — rank 3 of 10 in Pharma - Others · 87% evidence confidence
Syncom Formulations (India) Ltd scores 64.2 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.6 + 17.8 + 9.4 + 15.4 = 64.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Syncom Formulations (India) Ltd reported ₹126 Cr of revenue in the Jun 26 quarter, +7.7% year on year. Over 13 years it has compounded at 11.8% a year. The last full year, FY26, came in at ₹489 Cr. The last four reported quarters add to ₹498 Cr.
FY26 revenue came in at ₹489 Cr (+5.6% on the year), capping 13 years at 11.8% compound. The latest quarter (Jun 26) printed ₹126 Cr, +7.7% year on year.
Pace check: the last four quarters averaged +1.9% growth against the decade's 11.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.4% over the last 4 quarters against +30.8%/yr over the last 8 — rolling over; TTM profit +48.3% vs +72.2%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Syncom Formulations (India) Ltd's operating margin is 21.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 9.0% to 16.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 21.0%, +7.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0%–16.0%, and FY26's 16.0% is the top of that band — a record year.
Why the margin moved: operating margin went +7.4 pp year on year while gross margin went +6.7 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Syncom Formulations (India) Ltd earned ₹25.0 Cr of net profit in the Jun 26 quarter, +56.3% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹76.0 Cr. The 13-year compound rate is 21.6%. That is 19.8% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Jun 26 profit was ₹25.0 Cr, +56.3% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹76.0 Cr (+55.1%), and the 13-year compound rate is 21.6%.
Why profit moved: revenue contributed +7.7% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +49.0% vs revenue +1.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 50% of Syncom Formulations (India) Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹58.0 Cr of operating cash against ₹76.0 Cr of profit. After ₹66.0 Cr of capital spending, ₹−8.0 Cr was left as free cash.
FY26: operating cash of ₹58.0 Cr against reported profit of ₹76.0 Cr, leaving free cash of ₹−8.0 Cr after ₹66.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 50% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 50%: the cash cycle stretched 41 days between FY17 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 41 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Syncom Formulations (India) Ltd's cash conversion cycle runs 68 days in FY26, up from 27 days in FY17. Capital spending ran ₹84.0 Cr over the last 3 years. At FY26 sales of ₹489 Cr each day of that cycle holds about ₹1.3 Cr, so roughly ₹91.0 Cr sits inside the business at any moment.
FY26: debtors at 82 days, inventory at 81 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 68 days, looser than FY17's 27.
The full loop: cash goes out to suppliers and production on day 0; stock waits 81 days to sell; customers pay about 82 days after that; and suppliers themselves are paid at 96 days — netting out to the 68-day cycle.
In money terms: at FY26 sales of ₹489 Cr, each day of the cycle holds about ₹1.3 Cr — so the 68-day loop keeps roughly ₹91.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹84.0 Cr over the last 3 fiscal years against ₹17.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Syncom Formulations (India) Ltd earns a ROCE of 27% in FY26. That is up from a trough of 10% in FY23. Return on invested capital clears the cost of that capital by +8.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.5% net margin on 0.92× asset turns.
FY26 ROCE is 27%, recovered from a FY23 trough of 10% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 15.5% net margin × 0.92× asset turns × 1.29× balance-sheet leverage ≈ 18.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 20.2% − 12.0% = a +8.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Syncom Formulations (India) Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹415 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.26 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹415 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.26 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Syncom Formulations (India) Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 50.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.3 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 50.6%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Syncom Formulations (India) Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Shukra Pharmaceuticals LtdSHUKRAPHAR | 75.5/100Favorable setup74% evidence | 30.5/35 Revenue 100% · PAT 100% · OPM change 57 pp 95% evidence | 19.1/25 ROCE 36.9% · OPM 81% 95% evidence | 9.3/20 P/E 70× · PEG — 15% evidence | 16.6/20 RS sector 49.8% · RS bench 40.5% · 1Y 94%9 of 12 weeks ahead 70% evidence | |
| Exact sum: 30.5 + 19.1 + 9.3 + 16.6 = 75.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2JOJO Ltd531910 | 64.9/100Mixed-positive evidence61% evidence | ASLEEP | 26.3/35 Revenue 100% · PAT 100% · OPM change 53.1 pp 71% evidence | 14.2/25 ROCE 17% · OPM 44.7% 76% evidence | 8.9/20 P/E 218× · PEG — 15% evidence | 15.5/20 RS sector 4.3% · RS bench 86.8% · 1Y -6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 26.3 + 14.2 + 8.9 + 15.5 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Syncom Formulations (India) Ltdthis pageSYNCOMF | 64.2/100Mixed-positive evidence87% evidence | BREAKING OUT | 21.6/35 Revenue 0.4% · PAT 48.3% · OPM change 7 pp 95% evidence | 17.8/25 ROCE 26.8% · OPM 21% 95% evidence | 9.4/20 P/E 21.4× · PEG — 50% evidence | 15.4/20 RS sector -1% · RS bench 35.2% · 1Y 13.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 17.8 + 9.4 + 15.4 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Remus Pharmaceuticals LtdREMUS | 54.2/100Mixed-positive evidence70% evidence | TURNING | 19.2/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 14.6/25 ROCE 16.8% · OPM 7% 95% evidence | 10.7/20 P/E 28× · PEG — 50% evidence | 9.7/20 RS sector -10.3% · RS bench 22.1% · 1Y 4.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 14.6 + 10.7 + 9.7 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Sun Pharma Advanced Research Company LtdSPARC | 52.6/100Mixed-positive evidence81% evidence | FADING | 17.7/35 Revenue 100% · PAT 100% · OPM change 455 pp 74% evidence | 13.0/25 ROCE 164% · OPM -85% 100% evidence | 15.0/20 P/E 4× · PEG — 50% evidence | 6.9/20 RS sector -9% · RS bench 22.2% · 1Y 35.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 13 + 15 + 6.9 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Jenburkt Pharmaceuticals Ltd524731 | 50.7/100Mixed-positive evidence78% evidence | 16.5/35 Revenue 11.8% · PAT 6.1% · OPM change 6 pp 83% evidence | 19.1/25 ROCE 27.2% · OPM 32% 76% evidence | 9.0/20 P/E 13.2× · PEG — 50% evidence | 6.1/20 RS sector -9.9% · RS bench 0.4% · 1Y -3%0 of 1 week ahead to 2026-06-28 100% evidence | |
| Exact sum: 16.5 + 19.1 + 9 + 6.1 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7TTK Healthcare LtdTTKHLTCARE | 43.4/100Mixed-negative evidence81% evidence | BREAKING OUT | 16.8/35 Revenue 8.6% · PAT 17.5% · OPM change 4.8 pp 95% evidence | 7.1/25 ROCE 8% · OPM 6% 95% evidence | 13.0/20 P/E 20.6× · PEG — 50% evidence | 6.5/20 RS sector -20.5% · RS bench 12.9% · 1Y -3.1%10 of 10 weeks ahead 70% evidence |
| Exact sum: 16.8 + 7.1 + 13 + 6.5 = 43.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Unichem Laboratories LtdUNICHEMLAB | 40.9/100Mixed-negative evidence67% evidence | LEADER | 12.8/35 Revenue 7.2% · PAT 100% · OPM change 6.7 pp 71% evidence | 6.9/25 ROCE 4.1% · OPM 11% 76% evidence | 9.6/20 P/E 31.1× · PEG — 15% evidence | 11.6/20 RS sector -7.4% · RS bench 25.8% · 1Y 7.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.9 + 9.6 + 11.6 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Panacea Biotec LtdPANACEABIO | 24.1/100Adverse evidence80% evidence | ASLEEP | 11.7/35 Revenue 10.3% · PAT -80% · OPM change 3.5 pp 100% evidence | 1.6/25 ROCE -2.4% · OPM 2.8% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.8/20 RS sector -26.9% · RS bench -0.4% · 1Y -2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.6 + 10 + 0.8 = 24.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Madhuveer Com 18 Network LtdMADHUVEER | 47.8/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 68.7% · PAT 12.8% · OPM change 18.4 pp 53% evidence | 9.3/25 ROCE -1.1% · OPM 69.7% 57% evidence | 8.5/20 P/E 660× · PEG — 15% evidence | 13.8/20 RS sector 14.3% · RS bench 6.3% · 1Y -3.3%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 9.3 + 8.5 + 13.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Syncom Formulations (India) Ltd's share price today?
Syncom Formulations (India) Ltd trades at ₹19.5, +8.5% over the past year. The company is valued at ₹1,829 Cr. The stock sits at 89% of its 52-week range of ₹11–₹21, +28.9% versus its 200-day average. On the tape, the price is in a downtrend, 52 weeks in. — as of 11 September 2026.
What were Syncom Formulations (India) Ltd's latest quarterly results?
Syncom Formulations (India) Ltd reported revenue of ₹126 Cr and net profit of ₹25.0 Cr for the Jun 26 quarter. Revenue rose 7.7% and profit rose 56.3% year on year. Earnings per share were ₹0.26. The operating margin was 21.0%, 7.0 pp higher than a year earlier. — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's revenue?
Syncom Formulations (India) Ltd reported revenue of ₹126 Cr in the Jun 26 quarter, +7.7% year on year. For the full FY26 fiscal year, revenue was ₹489 Cr (+5.6%). Over the last 13 years revenue compounded at 11.8% a year. — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's profit?
Syncom Formulations (India) Ltd earned ₹25.0 Cr of net profit in the Jun 26 quarter, +56.3% year on year — the 9th straight quarter of growth. Full-year FY26 profit was ₹76.0 Cr. The operating margin ran 21.0% in the latest quarter. — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's market cap?
Syncom Formulations (India) Ltd's market capitalisation is ₹1,829 Cr at a share price of ₹19.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's P/E ratio?
Syncom Formulations (India) Ltd trades at a P/E of 21.4×, at the 52nd percentile of its own 11-year range, against a long-run median of 20.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Syncom Formulations (India) Ltd pay a dividend?
Not in its latest year — Syncom Formulations (India) Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 6 of its last 10 reported fiscal years, so there is a history but no current dividend. — as of 11 September 2026.
Is Syncom Formulations (India) Ltd overvalued?
On its own history, Syncom Formulations (India) Ltd looks mid-range: its P/E of 21.4× sits at the 52nd percentile of its 11-year range (long-run median 20.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Syncom Formulations (India) Ltd growing?
Yes — Syncom Formulations (India) Ltd is growing: latest-quarter revenue +7.7% year on year, profit +56.3%, and the margin +7.0 pp at 21.0%. The 13-year compound rates are 11.8% (revenue) and 21.6% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Syncom Formulations (India) Ltd performing?
Syncom Formulations (India) Ltd is in a downtrend, 52 weeks in. Its latest quarter's revenue rose 7.7% and profit rose 56.3% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Syncom Formulations (India) Ltd in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +70.4% at its peak to +0.4% but is still expanding, ROCE lifting at 27.0%. The read comes from the last 12 quarters of growth (revenue growth +0.4% latest, profit growth +48.3% latest, eps growth +46.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Syncom Formulations (India) Ltd in an uptrend?
No — the price is in a downtrend (week 52 of stage 4), trading +28.9% versus its 200-day average and at 89% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Syncom Formulations (India) Ltd beating the market?
On recent form, yes — Syncom Formulations (India) Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +720% against the NIFTY 500's +273% — ahead of the index over the full window. — as of 11 September 2026.
Will Syncom Formulations (India) Ltd's share price go up?
This page publishes no price forecast for Syncom Formulations (India) Ltd. What it measures instead: the share price is ₹19.5, the price is in a downtrend 52 weeks in. Its P/E of 21.4× sits at the 52nd percentile of its own 11-year range. — as of 11 September 2026.
Who owns Syncom Formulations (India) Ltd?
Promoters hold 50.6% of Syncom Formulations (India) Ltd, foreign institutions 0.3%, domestic institutions null% and the public 49.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Syncom Formulations (India) Ltd have too much debt?
No — Syncom Formulations (India) Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 77×. FY26 borrowings were ₹1.0 Cr against equity of ₹415 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's capex?
Syncom Formulations (India) Ltd spent ₹84.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹66.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Syncom Formulations (India) Ltd's cash flow?
Syncom Formulations (India) Ltd generated ₹58.0 Cr of operating cash flow in FY26 and ₹−8.0 Cr of free cash flow after ₹66.0 Cr of capital spending. Reported profit that year was ₹76.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Syncom Formulations (India) Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 50% of Syncom Formulations (India) Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹58.0 Cr against reported profit of ₹76.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 11 September 2026.
Where is Syncom Formulations (India) Ltd in its business cycle?
Syncom Formulations (India) Ltd's FY26 operating margin was 16.0%, against a 10-year band of 9.0%–16.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Syncom Formulations (India) Ltd's price assume?
At its price on 13 June 2026, Syncom Formulations (India) Ltd was priced for profit growth of about 8.3% a year. Profit itself has compounded 21.6% a year over the past 13 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Syncom Formulations (India) Ltd story?
The sharpest disagreement: profits are rising, but only 50% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Syncom Formulations (India) Ltd a stock worth studying right now?
This is not investment advice. The machine read: Syncom Formulations (India) Ltd's earnings have outrun its stock. EPS grew +52.8% in a year against a +8.5% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!